Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125499 | 0.90 | MAPT (0.35) | NPC1MAPTRAB9AACHECA1 | |
| SCHEMBL3025924 | 0.88 | NPC1 (0.36) | NPC1MAPTRAB9ACA1CA2 | |
| SCHEMBL28558026 | 0.87 | MAPT (0.34) | NPC1MAPTRAB9AACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL30042005 | 0.87 | MAPT (0.35) | NPC1MAPTRAB9AACHECA1 | |
| Iodide SCHEMBL1502876 | 0.87 | MAPT (0.34) | NPC1MAPTRAB9AACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL636092 | 0.87 | MAPT (0.35) | NPC1MAPTRAB9AACHECA1 | |
| SCHEMBL28817308 | 0.87 | MAPT (0.34) | NPC1MAPTRAB9AACHEALDH1A1 | |
| Bromide SCHEMBL636300 | 0.87 | ACHE (0.37) | NPC1MAPTRAB9AACHEALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4202272 | 0.87 | MAPT (0.34) | NPC1MAPTRAB9AACHEALDH1A1 | |
| Water SCHEMBL2150507 | 0.87 | ACHE (0.37) | NPC1MAPTRAB9AACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120069418-A1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | SIEMENS AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120069418-A1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | HCN2, EPX, HCN4 | NPC1 4367/4885MAPT 1912/4885RAB9A 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.